Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Azelastine eye drops receive FDA approval
Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.
Key Points
Solna, Sweden-Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.
The substance azelastine is an antihistamine, and the eye-drop formulation is approved for treatment of allergic conjunctivitis in adults and children.
Meda is conducting a broad development program for the substance, both as eye drops and nasal spray. The azelastine eye drops sample is one part of that development.
Related Videos
Related Content
